SOUTH SAN FRANCISCO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Exelixis, Inc. will release its 2007 third quarter financial results on Monday, November 5, 2007, after the markets close. The announcement will be followed by a live webcast at 2:00 p.m. PST/5:00 p.m. EST, in which Exelixis management will discuss the third quarter financial results and general business updates. The webcast may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.
An archive of this webcast will be available until 8:59 p.m. PST/11:59 p.m. EST on December 5, 2007. Access numbers for this replay are 1-888-286- 8010 (domestic) and 1-617-801-6888 (international); the replay passcode number is 57829707.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis’ broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company’s web site at http://www.exelixis.com.
CONTACT: Charles Butler, Director, Investor Relations, +1-650-837-7277,
cbutler@exelixis.com, or Hal Mackins, +1-650-837-7012, both of Exelixis,
Inc.
Web site: http://www.exelixis.com//
